远程医疗公司Hims & Hers Health Inc(HIMS.O)今日盘中大涨5.06%,引发市场关注。
分析师表示,HIMS提供的GLP-1类减肥药复方制剂在消费者中颇受欢迎,被视为该公司高增长的收入来源。大约一半对服用GLP-1药物感兴趣的受访者尚未决定选择品牌药还是复方药,这为复方药物在未来有较大的普及空间。
在愿意使用远程医疗平台获取GLP-1治疗的患者中,HIMS是最受认可的品牌之一。该公司以较实惠的价格提供方便获取药物和医疗服务的渠道,符合了消费者需求。分析师认为,加之公司核心业务增长强劲和较高运营杠杆,HIMS明年前景值得期待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.